FREE SHIPPING ON ORDERS OVER $150

glp-1 cardiovascular outcome trials and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Review of Cardiovascular Outcome Trials

$27.84

Quantity
- +
Description

No, chest pain is not considered a common side effect of the medication

glp-1 cardiovascular outcome trials and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Review of Cardiovascular Outcome Trials

JCI Insight 3(18):e121495

glp-1 cardiovascular outcome trials and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Review of Cardiovascular Outcome Trials

Endocr Pract (2016) 22 Suppl 3:1203

glp-1 cardiovascular outcome trials and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Review of Cardiovascular Outcome Trials

[DOI] [PubMed] [Google Scholar] 794.Giralt M., Vergara P

glp-1 cardiovascular outcome trials and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Review of Cardiovascular Outcome Trials

You may also like

recommand products